RPS: 'Clarity' needed on Priadel pricing once 5-year agreement ends
The RPS has sought assurances that the price of bipolar drug Priadel will not soar again once the five-year agreement between the government and the manufacturer expires.
The RPS has sought assurances that the price of bipolar drug Priadel will not soar again once the five-year agreement between the government and the manufacturer expires.